Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Commissioner Martin Makary said the agency would, whenever possible, restrict drug company employees from participating as ...

The leaked budget draft, if approved by Congress, would reduce the FDA’s budget authority, indicating more disruption could ...

The drug, orforglipron, helped people with diabetes reduce their blood sugar levels while spurring significant weight loss, ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

Rare diseases, often referred to as orphan diseases, affect small patient populations, yet collectively they impact more than ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...